Serina Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Serina Therapeutics, Inc. (SER) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of -$64.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-25
- Serina Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was -$64.00K, a 107.46% decline from fiscal 2024.
- Serina Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $858.00K, a 52.81% decline from fiscal 2023.
- Serina Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $1.82M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$64.00K 10-K · filed 2026-03-25 | |
| 2024-12-31 | $858.00K 10-K · filed 2026-03-25 | $4.33M 10-K · filed 2025-03-24 |
| 2023-12-31 | $1.82M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |